Higher plasma levels of lysophosphatidylcholine 18:0 are related to a lower risk of common cancers in a prospective metabolomics study

BMC Medicine
Tilman KuhnRudolf Kaaks

Abstract

First metabolomics studies have indicated that metabolic fingerprints from accessible tissues might be useful to better understand the etiological links between metabolism and cancer. However, there is still a lack of prospective metabolomics studies on pre-diagnostic metabolic alterations and cancer risk. Associations between pre-diagnostic levels of 120 circulating metabolites (acylcarnitines, amino acids, biogenic amines, phosphatidylcholines, sphingolipids, and hexoses) and the risks of breast, prostate, and colorectal cancer were evaluated by Cox regression analyses using data of a prospective case-cohort study including 835 incident cancer cases. The median follow-up duration was 8.3 years among non-cases and 6.5 years among incident cases of cancer. Higher levels of lysophosphatidylcholines (lysoPCs), and especially lysoPC a C18:0, were consistently related to lower risks of breast, prostate, and colorectal cancer, independent of background factors. In contrast, higher levels of phosphatidylcholine PC ae C30:0 were associated with increased cancer risk. There was no heterogeneity in the observed associations by lag time between blood draw and cancer diagnosis. Changes in blood lipid composition precede the diagnosis of c...Continue Reading

References

Oct 16, 1999·International Journal of Cancer. Journal International Du Cancer·V ChajèsE Riboli
Jul 3, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Zhenwen ZhaoYan Xu
Dec 7, 2007·Epidemiologic Perspectives & Innovations : EP+I·Sangita KulathinalKari Kuulasmaa
Nov 1, 2008·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Francisco MansillaKarin Birkenkamp-Demtröder
Oct 27, 2009·Cell Cycle·Shuying LiuGordon B Mills
Sep 21, 2011·Urologic Oncology·Bruce J Trock
Oct 18, 2011·Cancer Metastasis Reviews·Anna J S Houben, Wouter H Moolenaar
Jul 7, 2012·Journal of Cellular Physiology·M Luísa DóriaLuisa A Helguero
Aug 2, 2012·Briefings in Bioinformatics·Cosmin LazarAnn Nowé
Feb 12, 2013·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Joshua N SampsonSteven C Moore
Apr 16, 2013·International Journal of Molecular Sciences·Yunping QiuWei Jia
Jul 10, 2013·BMC Medical Research Methodology·Xiaonan XueHoward D Strickler
Jul 31, 2013·Clinical Chemistry·Mary K TownsendBrian M Wolpin
Oct 8, 2013·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·David B LiesenfeldCornelia M Ulrich
Feb 8, 2014·Omics : a Journal of Integrative Biology·Eun Ji JooRobert J Linhardt
May 29, 2014·The Journal of Endocrinology·Karsten Suhre
Jun 5, 2014·Cancer·Amanda J CrossJoshua N Sampson
Feb 17, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Eman Abdelzaher, Mohamed Farouk Mostafa
Apr 24, 2015·International Journal of Cancer. Journal International Du Cancer·Alison M MondulDemetrius Albanes
Dec 5, 2015·Journal of Diabetes Research·Matthias S Klein, Jane Shearer

❮ Previous
Next ❯

Citations

May 11, 2017·International Journal of Obesity : Journal of the International Association for the Study of Obesity·B EnglichK M Junge
May 13, 2017·Journal of Pharmaceutical Sciences·Keiko MaekawaYoshiro Saito
Jan 25, 2018·International Journal of Epidemiology·Lucie LécuyerMathilde Touvier
Jan 24, 2018·Frontiers in Oncology·Márcia Cristina Fernandes MessiasPatrícia de Oliveira Carvalho
Aug 9, 2018·Nature Communications·Deniz Senyilmaz-TiebeAurelio A Teleman
Nov 28, 2018·Medical Sciences : Open Access Journal·Gohar HakobyanYuri Tadevosyan
Jan 22, 2019·International Journal of Cancer. Journal International Du Cancer·Anne J M R GeijsenCornelia M Ulrich
Feb 20, 2019·International Journal of Cancer. Journal International Du Cancer·Jiaqi HuangDemetrius Albanes
Apr 6, 2019·International Journal of Cancer. Journal International Du Cancer·Julie A SchmidtRuth C Travis
Jan 17, 2020·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Rajkumar VutukuriRobert Brunkhorst
Feb 6, 2020·The Journal of Clinical Endocrinology and Metabolism·Jinnan LiuXilin Yang
May 31, 2019·Metabolomics : Official Journal of the Metabolomic Society·Lianyuan TaoLijun Zhong
Sep 25, 2019·BMC Medicine·Mathilde HisSabina Rinaldi
Oct 27, 2017·Mass Spectrometry Reviews·Minnie JacobAnas M Abdel Rahman
Apr 25, 2020·Cancers·Ariadna Martín-BlázquezOctavio Caba
Jul 1, 2020·International Journal of Molecular Sciences·Eva Knuplez, Gunther Marsche
Oct 18, 2019·Current Developments in Nutrition·M Isabel OrdizMark J Manary
Sep 9, 2020·Metabolomics : Official Journal of the Metabolomic Society·Noriko NakamuraRichard D Beger
Apr 20, 2018·NMR in Biomedicine·Guro F GiskeødegårdTone F Bathen
Jun 4, 2019·American Journal of Epidemiology·Bing YuSteven C Moore
Mar 5, 2019·Metabolomics : Official Journal of the Metabolomic Society·A W L BayciR Keidan
Feb 1, 2020·BMC Medicine·Steven C Moore
Sep 13, 2016·Metabolomics : Official Journal of the Metabolomic Society·Emily G Armitage, Andrew D Southam
Mar 13, 2019·Metabolites·Nuria Gómez-CebriánLeonor Puchades-Carrasco
Aug 6, 2019·European Urology Oncology·Ying WangVictoria L Stevens

❮ Previous
Next ❯

Methods Mentioned

BETA
blood draw

Software Mentioned

[UNK]
SAS

Related Concepts

Related Feeds

Cancer Metabolic Reprogramming (Keystone)

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.

Cancer Metabolic Reprogramming

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.

Cancer -Omics

A variety of different high-throughput technologies can be used to identify the complete catalog of changes that characterize the molecular profile of cohorts of tumor samples. Discover the latest insights gained from cancer 'omics' in this feed.